Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-4-26
pubmed:abstractText
To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma. To evaluate response and its duration after administration of intravenous Etoposide, methylprednisolone, high-dose cytosine arabinoside, and cisplatin (ESHAP) as consolidation therapy after complete or partial responses (CR or PR, respectively) or after crossover therapy for progressive disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0167-6997
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
217-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7896540-Adolescent, pubmed-meshheading:7896540-Adult, pubmed-meshheading:7896540-Aged, pubmed-meshheading:7896540-Aged, 80 and over, pubmed-meshheading:7896540-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7896540-Cisplatin, pubmed-meshheading:7896540-Cross-Over Studies, pubmed-meshheading:7896540-Cytarabine, pubmed-meshheading:7896540-Etoposide, pubmed-meshheading:7896540-Female, pubmed-meshheading:7896540-Humans, pubmed-meshheading:7896540-Ifosfamide, pubmed-meshheading:7896540-Lymphoma, pubmed-meshheading:7896540-Male, pubmed-meshheading:7896540-Mesna, pubmed-meshheading:7896540-Methylprednisolone, pubmed-meshheading:7896540-Methylprednisolone Hemisuccinate, pubmed-meshheading:7896540-Middle Aged, pubmed-meshheading:7896540-Mitoxantrone, pubmed-meshheading:7896540-Prednisone, pubmed-meshheading:7896540-Salvage Therapy
pubmed:year
1994
pubmed:articleTitle
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
pubmed:affiliation
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II